Innoviva Reports Fourth Quarter 2021 Financial Results
Innoviva, Inc. (NASDAQ: INVA) (Innoviva and the Company) today reported financial results for the fourth quarter and the year ended December 31, 2021.
- Innoviva, Inc. (NASDAQ: INVA) (Innoviva and the Company) today reported financial results for the fourth quarter and the year ended December 31, 2021.
- Pavel Raifeld, Chief Executive Officer of Innoviva, Inc., stated Our royalty revenues in the fourth quarter grew 18% year over year, displaying strong positive momentum in a volatile environment.
- Fourth quarter 2021 net sales of RELVAR/BREO ELLIPTA by GSK were $384.4 million, up 3% from $372.8 million in the fourth quarter of 2020, with $158.2 million in net sales from the U.S. market and $226.2 million from non-U.S. markets.
- Fourth quarter 2021 net sales of ANORO ELLIPTA by GSK were $166.7 million, down 17% from $200.9 million in the fourth quarter of 2020, with $85.3 million net sales from the U.S. market and $81.4 million from non-U.S. markets.